百令胶囊与斯奇康联合治疗慢阻肺缓解期的临床分析

Clinical Analysis of Corbrin Capsule and Siqikang in Treatment of Chronic Obstructive at Remittent Stage

目的探讨百令胶囊与斯奇康联合治疗慢阻肺(COPD)缓解期的临床效果及安全性。方法便利选择2012年7月—2013年7月期间该院收治的50例慢阻肺缓解期患者作为研究对象,并随机分为观察组和对照组,每组25例,观察组给予百令胶囊与斯奇康联合治疗,对照组给予单一百令胶囊治疗。观察两组患者的急性发作次数、住院次数、死亡人数及肺功能下降指标。结果观察组3年期间内的急性发作人数(8、10、11例)、平均天数(11.2±2.0)、(8.6±1.9)、(8.9±2.3)d,发作后的平均住院天数(8.3±1.3)、(7.3±1.6)、(5.3±0.9)d等均明显优于对照组,组间差异有统计学意义(P<0.05);观察组治疗后的肺功能指标[FVC(1.6±0.2)V/L、FEV1(61.3±0.9)%、FEV1/FVC(63.6±0.7)%]显著优于对照组,组间差异有统计学意义(P<0.05)。结论百令胶囊与斯奇康联合治疗COPD的临床疗效显著,能够显著提高患者的抵抗能力,预防呼吸道感染引起的慢阻肺急性发作,提高患者的生存质量。

Objective To discuss the clinical effect and safety of corbrin capsule and siqikang in treatment of chronic obstructive at remittent stage. Methods Convenient selection 50 cases of patients with chronic obstructive at remittent stage admitted and treated in our hospital from July 2012 to July 2013 were selected as the research objects and randomly divided into two groups with 25 cases in each, the observation group were treated with corbrin capsule and siqikang, while the control group were treated with corbrin capsule, and the acute attack frequency, hospitalization time, death number and lung function decrease indexes of the two groups were observed. Results The acute attack number（ 8 cases, 10 cases and 11cases）, average time（11.2±2.0）,（8.6±1.9）,（8.9±2.3）d and the average length of stay after attack（8.3±1.3）,（7.3±1.6）,（5.3±0.9）d in the observation group within 3 years were obviously better than those in the control group, and the differences had statistical significance（P 0.05）, after treatment, the lung function indexes [FVC（1.6 ±0.2）V/L,FEV1（61.3 ±0.9）%,FEV1/FVC（63.6±0.7）%]in the observation group were obviously better than those in the control group, and the differences between groups had statistical significance（P〈0.05）. Conclusion The clinical curative effect of corbrin capsule and siqikang in treatment of COPD is obvious, which can obviously improve the resistance ability of patients, prevent the acute attack of chronic obstructive caused by the respiratory tract infection and improve the quality of life of patients.